scispace - formally typeset
Search or ask a question
Institution

ACADIA Pharmaceuticals Inc.

CompanySan Diego, California, United States
About: ACADIA Pharmaceuticals Inc. is a company organization based out in San Diego, California, United States. It is known for research contribution in the topics: Pimavanserin & Receptor. The organization has 260 authors who have published 276 publications receiving 8418 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: In this article, temporary tethering using aluminum or zinc in Diels-Alder reactions made possible the use of otherwise "noncompatible" combinations of dienes and dienophiles, resulting in the one-step formation of substituted cyclohexene 1,2bis-methanols.
Abstract: (formula presented) Temporary tethering using aluminum or zinc in Diels-Alder reactions made possible the use of otherwise "noncompatible" combinations of dienes and dienophiles, resulting in the one-step formation of substituted cyclohexene 1,2-bis-methanols. Excellent regioselectivity and also significant stereoselectivity were obtained.
Patent
30 Oct 2007
TL;DR: In this paper, the authors proposed a method for identifying a subject suitable for treatment using 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators.
Abstract: The present invention relates to optionally substituted 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; compositions comprising the same; methods of inhibiting an activity of a monoamine receptor with said compounds; methods of treating a disease condition associated with a monoamine receptor using said compounds; and methods for identifying a subject suitable for treatment using said compounds.
Journal ArticleDOI
TL;DR: The authors evaluated the palatability and swallowability of the contents of pimavanserin 34 mg capsules mixed with selected soft foods or a liquid nutritional supplement and found that the capsule manipulation to allow sprinkling of contents was rated as easy to "very easy" or "somewhat easy".
Abstract: Dysphagia (difficulty swallowing) affects up to 13% of persons 65 years and older and 51% of older persons in nursing homes and can contribute to reduced adherence to oral medications. This was an exploratory, single-center, open-label, randomized, crossover study in healthy older adult participants. Primary objectives were evaluation of palatability (taste) and swallowability of the contents of pimavanserin 34 mg capsules mixed with selected soft foods or a liquid nutritional supplement. Secondary objectives included evaluation of additional palatability endpoints and ease of capsule manipulation for mixing. A total of 18 healthy, older adult participants (mean age 65 years) were included. Mean participant ratings for all food vehicles were “moderately like” to “neither like nor dislike” for palatability and “very easy” to “somewhat easy” for swallowability. Capsule manipulation to allow sprinkling of contents was rated “very easy” or “somewhat easy” by most participants. There were five treatment-emergent adverse events, all mild; two were deemed related to study treatment. The palatability and swallowability of pimavanserin was considered acceptable when administered with certain soft foods or a liquid nutritional supplement by the study participants.
Journal ArticleDOI
TL;DR: A significant increase in the mortality rate for participants taking concurrent antipsychotics compared with the group not taking antipsychotic medications was highlighted, highlighting a significant risk of mortality, and severe AEs in patients with Parkinson disease receiving atypical antippsychotics.
Patent
18 Nov 2005
TL;DR: In this article, a method and a test kit for identifying substances that act as ligands, corepressors, coactivators, agonist and antagonists for cloned nuclear hormone receptors is presented.
Abstract: A method and kit developed to identify substances that act as ligands, corepressors, coactivators, agonist and antagonists for cloned nuclear hormone receptors, as well as a test kit for use in the methods is provided herein. More specifically, the method involves expressing a nuclear hormone receptor, receptor heterodimer, and/or receptor homodimer, DNA encoding one or more signaling molecules and DNA encoding a marker, incubating the cells with a test substance, and identifying whether the test substance interacts with the receptor quantitatively or qualitatively by identifying the amount of marker and/or the proliferation of the cells.

Authors

Showing all 261 results

Network Information
Related Institutions (5)
Eli Lilly and Company
22.8K papers, 946.7K citations

81% related

Pfizer
37.4K papers, 1.6M citations

81% related

AstraZeneca
23.4K papers, 938.2K citations

80% related

Merck & Co.
48K papers, 1.9M citations

80% related

Scripps Research Institute
32.8K papers, 2.9M citations

80% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20231
202119
202016
20196
20188
20176